View Article

Abstract

The groundbreaking TEMPO 3:4 trial, which served as the basis for tolvaptan's approval, represented a revolution in the treatment of autosomal dominant polycystic kidney disease (ADPKD). Through this advancement, patient management for ADPKD has evolved from using broad strategies to stop the progression of chronic kidney disease to focusing on disease-specific mechanisms. Evidence-based strategies to start treatment only in patients with quickly worsening disease are essential, though, given the long-term nature of this medication and associated side effects. The European Renal Association (ERA) policy statement, released in 2016, was the first society-based guideline on the usage of tolvaptan and has been a popular resource for nephrologists when making decisions. Since then, there has been a significant accumulation of practical knowledge regarding the use of tolvaptan in ADPKD.

Keywords

ADPKD; polycystic kidney disease; position statement; tolvaptan; vasopressin V2 receptor antagonist

Reference

  1. Zilberberg MD, Exuzides A, Spalding J, et al. Epidemiology, clinical and economic outcomes of admission hyponatremia among hospitalized patients. Curr Med Res Opin. 2008;24(6):1601–1608.
  2. Verbalis JG, Goldsmith SR, Greenberg A, et al. Hyponatremia treatment guidelines 2007: Expert panel recommendations. Am J Med. 2007;120(11A):S1–S21. 
  3. Rockville, MD: Otsuka America Pharmaceutical, Inc.; May 2009. Samsca (tolvaptan), package insert. 
  4. Schrier RW, Gross P, Gheorghiade M, et al.for the SALT Investigators Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355:2099–2112.
  5. Gheorghiade M, Konstam MA, Burnett JC, et al.for the EVEREST Investigators Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST Clinical Status Trials. JAMA. 2007;297:1332–1343.
  6. Konstam MA, Gheorghiade M, Burnett JC, et al.for the EVEREST Investigators Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST Outcome Trial. JAMA. 2007;297:1319–1331.
  7. Schrier RW, Gross P, Gheorghiade M, et al.for the SALT Investigators Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355:2099–2112. 
  8. Gheorghiade M, Konstam MA, Burnett JC, et al.for the EVEREST Investigators Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST Clinical Status Trials. JAMA. 2007;297:1332–1343
  9. Konstam MA, Gheorghiade M, Burnett JC, et al.for the EVEREST Investigators Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST Outcome Trial. JAMA. 2007;297:1319–1331.
  10. Structure of Tolvaptan - https://web.chemdoodle.com/demos/iupac-naming#customise-template
  11. Indian Pharmacopoeia - 2022,  Ninth Edition, Volume – III, Page number: 3832, Chebrolu Hanumaiah Institute of Pharmaceutical Sciences, Chowdavaram, Guntur, Andhra Pradesh, India.

Photo
Kondeti Venkata Surya Siva Kumar
Corresponding author

Department of Pharmacology and Pharmaceutics, Chebrolu Hanumaiah Institute of Pharmaceutical Sciences, Chandramoulipuram, Chowdavaram, Guntur, Andhra Pradesh – 522019, India

Photo
Saripella Jaya Sree
Co-author

Department of Pharmacology and Pharmaceutics, Chebrolu Hanumaiah Institute of Pharmaceutical Sciences, Chandramoulipuram, Chowdavaram, Guntur, Andhra Pradesh – 522019, India

Photo
Saripella Latha Sree
Co-author

Department of Pharmacology and Pharmaceutics, Chebrolu Hanumaiah Institute of Pharmaceutical Sciences, Chandramoulipuram, Chowdavaram, Guntur, Andhra Pradesh – 522019, India

Kondeti Venkata Surya Siva Kumar, Saripella Latha Sree and Saripella Jaya Sree, Tolvaptan - Vasopressin Antagonist for Hyponatremia, Int. J. in Pharm. Sci., 2023, Vol 1, Issue 8, 1-8. https://doi.org/10.5281/zenodo.8206257

More related articles
A Review on Particle Size Reduction of Active Phar...
Saurabh Patara, Snehal Jadhav, Sneha Jankar, Shreya Tondlikar, Pr...
High-Fat Diet-Induced Obesity in Rodents: Dietary ...
Hajera Begum, Dr. Koppala R. V. S. Chaitanya, Mahadev Anitha, Bom...
Biosurfactants as Pharmaceutical Excipients: Emerg...
Shahil Ghadage, Tushar Shelke, Priya Daingade...
Development of Sugar-Free Herbal Syrup of Clerodendrum inerme Using Stevia for D...
Sarthak Nehe, Samiksha Bichave, Sagar Vaidya, Nikita Jadhav, Manish Ahire, Manas Vyavahare, Gaurav P...
A Review on the Safety of Two Single-Inhaler Triple Therapy Regimens: Fluticason...
Jerin. M., Sam Jeeva Kumar, Dr. Shaiju Dharan, Dr. Chintha Chandran, Krishna B....
Related Articles
DNA Barcoding and Molecular Techniques for Authentication of Aloe vera – Revie...
Sumit Kor, Shreyash Pardeshi, Aditya Jamghare, Sahil Shirose, Avadhoot Partole, Raj Dohole, Yash Mul...
Emerging Herbal Strategies for the Management of Hyperpigmentation : Comprehensi...
Shubhangi Kasture, Shrutika Patil, Dnyaneshwar Sutar, Divesh Gavit, Ancy Keerthika, Akash Jambhale...
Clitoria ternatea Flower and ITS Bioactive Compounds;Potential Use as Microencap...
Snehal Jadhav, Sneha Jankar, Shreya Tondlikar, Saurabh Patara, Aditi Bangar, Pratiksha Pandit...
Phytosomes: A NOVEL Approach for HERBAL Drug Delivery – Review Article...
Sahil Shirose, Suyog Vishe, Monika Vinchu, Harshali Shelar, Aditya Jamghare, Avadhoot Partole...
A Review on Particle Size Reduction of Active Pharmaceutical Ingredients (APIs) ...
Saurabh Patara, Snehal Jadhav, Sneha Jankar, Shreya Tondlikar, Pratiksha Pandit, Aditi Bangar...
More related articles
A Review on Particle Size Reduction of Active Pharmaceutical Ingredients (APIs) ...
Saurabh Patara, Snehal Jadhav, Sneha Jankar, Shreya Tondlikar, Pratiksha Pandit, Aditi Bangar...
High-Fat Diet-Induced Obesity in Rodents: Dietary Composition, Adipose Remodelin...
Hajera Begum, Dr. Koppala R. V. S. Chaitanya, Mahadev Anitha, Bommu Vaishnavi...
Biosurfactants as Pharmaceutical Excipients: Emerging Applications...
Shahil Ghadage, Tushar Shelke, Priya Daingade...
A Review on Particle Size Reduction of Active Pharmaceutical Ingredients (APIs) ...
Saurabh Patara, Snehal Jadhav, Sneha Jankar, Shreya Tondlikar, Pratiksha Pandit, Aditi Bangar...
High-Fat Diet-Induced Obesity in Rodents: Dietary Composition, Adipose Remodelin...
Hajera Begum, Dr. Koppala R. V. S. Chaitanya, Mahadev Anitha, Bommu Vaishnavi...
Biosurfactants as Pharmaceutical Excipients: Emerging Applications...
Shahil Ghadage, Tushar Shelke, Priya Daingade...